Status:
COMPLETED
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.
Lead Sponsor:
Chong Kun Dang Pharmaceutical
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
19-65 years
Phase:
PHASE1
Brief Summary
This is a Randomized, open-label, single oral dosing, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of CKD-383 and the co-administ...
Detailed Description
Participants were randomly assigned in a 1:1 ratio. The patients are prescribed oral administration of the appropriate IP(2 or 4 tablets in single dose: actual medication)
Eligibility Criteria
Inclusion
- Healthy adults aged 19 to 65 years
- Based on screening, no congenital or chronic disease, who have no athological symptoms or findings(If necessary, EEG, ECG, chest and gastroscopy or gastrointestinal radiation, Examination)
- within 5 years prior to the start of the trial(Period 1 administration) of any clinically significant mental medical history
- Other inclusion criteria, as defined in the protocol
Exclusion
- who has taken drug metabolism enzyme induction and inhibitory drugs, such as barbitale drugs, within 30 days prior to the start of the trial (Period 1 administration)
- Other exclusive criteria, as defined in the protocol
Key Trial Info
Start Date :
April 4 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 17 2024
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06483243
Start Date
April 4 2024
End Date
May 17 2024
Last Update
July 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chung-Ang University Gwangmyeong Hospital
Gyeonggi-do, South Korea